Journey Medical Corporation
Quick facts
Phase 3 pipeline
- DFD-29 · Dermatology
DFD-29 is a topical antimicrobial agent designed to treat bacterial skin infections by disrupting bacterial cell function. - glycopyrronium Topical Wipes · Dermatology
Glycopyrronium is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce sweat gland secretion.
Phase 2 pipeline
- Dose 1 of glycopyrrolate, 2.0% QD
- Dose 1 of glycopyrronium, 2.5% QD · Ophthalmology
Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to reduced salivation and sweating. - Dose 2 of glycopyrrolate, 3.0% QD
- Dose 2 of glycopyrronium, 3.75% QD
- glycopyrrolate, 1.0%
- glycopyrrolate, 2.0%
- glycopyrrolate, 3.0%
- glycopyrrolate, 4.0%
- Glycopyrronium cloth, 2.4%
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Journey Medical Corporation
What is Journey Medical Corporation's pipeline?
Journey Medical Corporation has 2 drugs in Phase 3, 9 in Phase 2, 0 in Phase 1. Late-stage candidates include DFD-29, glycopyrronium Topical Wipes.
Related
- Sector hub: All tracked pharma companies